Bambermycins

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Bambermycins
Accession Number
DB11377
Type
Small Molecule
Groups
Vet approved
Description

Bambermycins are antibiotic complexes which are retrieved from the organism, Streptomyces bambergiensis. They are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
PP922A42V2
CAS number
Not Available
Weight
Average: 1597.609
Monoisotopic: 1596.660998224
Chemical Formula
C70H109N4O35P
InChI Key
FUIOWSNNCWZETH-NAMXWVJMSA-N
InChI
InChI=1S/C70H109N4O35P/c1-31(2)16-14-18-33(4)20-21-34(5)24-26-69(9,10)25-13-12-17-32(3)19-15-27-97-62(92)40(80)29-99-110(95,96)109-67-57(58(108-68(71)93)70(11,94)59(107-67)61(90)91)106-64-45(73-37(8)77)48(83)55(42(102-64)30-98-65-52(87)49(84)46(81)41(28-75)101-65)104-63-44(72-36(7)76)47(82)54(35(6)100-63)103-66-53(88)50(85)51(86)56(105-66)60(89)74-43-38(78)22-23-39(43)79/h13,16,19-20,25,35,40-42,44-59,63-67,75,78,80-88,94H,5,12,14-15,17-18,21-24,26-30H2,1-4,6-11H3,(H2,71,93)(H,72,76)(H,73,77)(H,74,89)(H,90,91)(H,95,96)/b25-13+,32-19+,33-20+/t35-,40-,41-,42-,44-,45-,46-,47-,48-,49+,50+,51-,52-,53-,54-,55-,56+,57-,58-,59-,63+,64+,65-,66-,67-,70+/m1/s1
IUPAC Name
(2S,3S,4R,5R,6R)-3-hydroxy-5-{[(2S,3R,4R,5S,6R)-4-hydroxy-5-{[(2S,3R,4R,5S,6R)-4-hydroxy-3-[(1-hydroxyethylidene)amino]-6-methyl-5-{[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-C-hydroxycarbonimidoyl]oxan-2-yl]oxy}oxan-2-yl]oxy}-3-[(1-hydroxyethylidene)amino]-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-6-({hydroxy[(2R)-2-hydroxy-3-oxo-3-{[(3E,7E,14E)-4,9,9,15,19-pentamethyl-12-methylideneicosa-3,7,14,18-tetraen-1-yl]oxy}propoxy]phosphoryl}oxy)-4-(C-hydroxycarbonimidoyloxy)-3-methyloxane-2-carboxylic acid
SMILES
[H]\C(CC\C(C)=C(/[H])CCOC(=O)[C@]([H])(O)COP(O)(=O)O[C@@]1([H])O[C@]([H])(C(O)=O)[C@@](C)(O)[C@]([H])(OC(O)=N)[C@@]1([H])O[C@]1([H])O[C@]([H])(CO[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O[C@]3([H])O[C@]([H])(C(O)=NC4=C(O)CCC4=O)[C@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])N=C(C)O)[C@]([H])(O)[C@@]1([H])N=C(C)O)=C(\[H])C(C)(C)CCC(=C)C\C([H])=C(/C)CCC=C(C)C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Bambermycins is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Bambermycins is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Bambermycins is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Bambermycins is combined with Acenocoumarol.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Bambermycins.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bambermycins.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Bambermycins.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bambermycins.
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Bambermycins.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Bambermycins.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Salmon RE, Stevens VI: Effect of bambermycins (Flavomycin) in diets for growing turkeys. Poult Sci. 1990 Jul;69(7):1133-40. [PubMed:2235832]
  2. George BA, Fagerberg DJ: Effect of bambermycins, in vitro, on plasmid-mediated antimicrobial resistance. Am J Vet Res. 1984 Nov;45(11):2336-41. [PubMed:6151815]
  3. Dealy J, Moeller MW: Influence of bambermycins on Salmonella infection and antibiotic resistance in swine. J Anim Sci. 1976 May;42(5):1331-6. [PubMed:773914]
  4. Dealy J, Moeller MW: Influence of bambermycins on Salmonella infection and antibiotic resistance in calves. J Anim Sci. 1977 May;44(5):734-8. [PubMed:324962]
  5. Firman JD, Kirn BN: Effects of monensin and bambermycins on the performance of market turkeys. Poult Sci. 1989 Dec;68(12):1724-6. [PubMed:2622825]
  6. Parks CW, Grimes JL, Ferket PR, Fairchild AS: The effect of mannanoligosaccharides, bambermycins, and virginiamycin on performance of large white male market turkeys. Poult Sci. 2001 Jun;80(6):718-23. [PubMed:11441837]
  7. Dealy J, Moeller MW: Effect of bambermycins on Escherichia coli and antibiotic resistance in calves. J Anim Sci. 1977 Dec;45(6):1239-42. [PubMed:342477]
  8. Hagsten I, Grant RJ, Meade RJ, O'Kelley R: Effect of bambermycins and tylosin on performance of growing-finishing swine. J Anim Sci. 1980 Mar;50(3):484-9. [PubMed:6965937]
  9. Johnston NL, Quarles CL, Fagerberg DJ: Long-term broiler performance with bambermycins and bambermycins plus roxarsone. Poult Sci. 1983 Jul;62(7):1189-94. [PubMed:6604910]
  10. Waldroup PW, Spencer GK, Waibel PE, Quarles CL, Grant RJ: The use of bambermycins (Flavomycin) and halofuginone (Stenorol) in diets for growing turkeys. Poult Sci. 1985 Jul;64(7):1296-301. [PubMed:3875089]
External Links
ChemSpider
4938687
Wikipedia
Bambermycin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.12 mg/mLALOGPS
logP2.31ALOGPS
logP-1.2ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)-3.5ChemAxon
pKa (Strongest Basic)11.07ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count36ChemAxon
Hydrogen Donor Count19ChemAxon
Polar Surface Area613.34 Å2ChemAxon
Rotatable Bond Count39ChemAxon
Refractivity388.82 m3·mol-1ChemAxon
Polarizability159.66 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as terpene glycosides. These are prenol lipids containing a carbohydrate moiety glycosidically bound to a terpene backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Terpene glycosides
Direct Parent
Terpene glycosides
Alternative Parents
Oligosaccharide phosphates / Fatty acyl glycosides / N-acyl-alpha-hexosamines / Glucuronic acid derivatives / O-glycosyl compounds / Monocyclic monoterpenoids / Dialkyl phosphates / Dicarboxylic acids and derivatives / Pyrans / Oxanes
show 18 more
Substituents
Oligosaccharide phosphate / Oligosaccharide / Terpene glycoside / Fatty acyl glycoside / N-acyl-alpha-hexosamine / Glucuronic acid or derivatives / Glycosyl compound / O-glycosyl compound / Monocyclic monoterpenoid / Monoterpenoid
show 37 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on February 25, 2016 11:16 / Updated on June 04, 2019 07:20